Ixekizumab (Psoriasis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 17
4 Disease Management 18
4.1 Treatment Overview 19
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Opportunity and Unmet Need 25
6.1 Overview 25
6.2 Unmet Needs 26
6.2.1 Improved Drug Safety and Efficacy Profiles 26
6.2.2 Biomarkers for Predicting Remission 27
6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 27
6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 28
6.2.5 An Effective Biologic/Systemic Topical Therapy 28
6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 29
6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 29
6.3 Opportunities 30
6.4 Unmet Needs Gap Analysis 30
6.4.1 Predictive Tools for Diagnosis and Treatment 31
6.4.2 Target Specificity 31
6.4.3 Topical Biologic/Systemic Therapeutic Options 32
6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 32
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 34
8 Ixekizumab (LY2439821) 36
8.1 Overview 36
8.2 Efficacy 37
8.3 Safety 38
8.4 Dosing and Formulation 38
8.5 Potential Clinical Positioning 38
8.6 Potential Commercial Positioning 39
8.7 Pricing and Reimbursement 39
8.8 SWOT Analysis 40
8.9 Forecast 41
9 Appendix 42
9.1 Bibliography 42
9.2 Abbreviations 44
9.3 Methodology 47
9.4 Forecasting Methodology 47
9.4.1 Diagnosed Psoriasis Patients 47
9.4.2 Percent Drug-Treated Patients 48
9.4.3 General Pricing Assumptions 48
9.4.4 Generic Erosion 49
9.4.5 Pricing of Pipeline agents 49
9.5 Physicians and Specialists Included in this Study 50
9.6 Primary Research – Prescriber Survey 51
9.7 About the Authors 52
9.7.1 Analysts 52
9.7.2 Global Head of Healthcare 53
9.8 About GlobalData 54
9.9 Disclaimer 54